Description:

NSABP PROTOCOL B-36 Treatment Form for 5-FU, Epirubicin, Cyclophosphamide (FEC) Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C87B6D74-9381-59FA-E034-0003BA12F5E7

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C87B6D74-9381-59FA-E034-0003BA12F5E7

Keywords:
Versions (3) ▾
  1. 8/26/12
  2. 12/12/14
  3. 1/8/15
Uploaded on:

January 8, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT00087178 Treatment - NSABP PROTOCOL B-36 Treatment Form for 5-FU, Epirubicin, Cyclophosphamide (FEC) - 2174958v3.0

No Instruction available.

  1. StudyEvent: NSABP PROTOCOL B-36 Treatment Form for 5-FU, Epirubicin, Cyclophosphamide (FEC)
    1. No Instruction available.
General information
Are data amended?
Summary Of 5-fu, Epirubicin, Cyclophosphamide
Cycle #
Unnamed question [agent name]
Was this cycle delayed for toxicity? (Circle Y or N for Yes, No)
Was growth factor support employed? (Circle Y or N for Yes, No)
Summary Of 5-fu, Epirubicin, Cyclophosphamide (continued)
Reason Treatment Ended (Select the reason that best explains why FEC has ended, or why the patient did not begin FEC.)

Similar models